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Purpose: Adjuvant chemotherapy (ACT) is used after surgery to prevent recurrence or metastases.
However, ACT for non-small cell lung cancer (NSCLC) is still controversial. This study aimed to develop
prediction models to distinguish who is suitable for ACT (ACT-beneﬁt) and who should avoid ACT
(ACT-futile) in NSCLC.
Methods: We identiﬁed the ACT correlated gene signatures and performed several types of ANN algo-
rithms to construct the optimal ANN architecture for ACT beneﬁt classiﬁcation. Reliability was assessed
by cross-data set validation.
Results: We obtained 2 probes (2 genes) with T-stage clinical data combination can get good prediction
result. These genes included 208893_s_at (DUSP6) and 204891_s_at (LCK). The 10-fold cross validation
classiﬁcation accuracy was 65.71%. The best result of ANN models is MLP14-8-2 with logistic activation
function.
Conclusions: Using gene signature proﬁles to predict ACT beneﬁt in NSCLC is feasible. The key to this anal-
ysis was identifying the pertinent genes and classiﬁcation. This study maybe helps reduce the ineffective
medical practices to avoid the waste of medical resources.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of can-
cer deaths in the worldwide [1]. Complete surgical resection with
adjuvant chemotherapy (ACT) is the most widely used treatment
for NSCLC. Adjuvant chemotherapy is used after surgery to prevent
recurrence or metastases. According to guidelines from medical
society, cisplatinum based ACT is now recommend a standard
treatment in NSCLC. Several large randomized studies have tried
to understand the beneﬁt of ACT in NSCLC [2–5]. However, adju-
vant chemotherapy for non-small cell lung cancer is still contro-
versial [6]. Especially in the treatment of early-stage (IB) NSCLC
is unclear in clinical oncology. Furthermore, several studies report
opposite outcomes of adjuvant chemotherapy in NSCLC [4,7].
Because adjuvant chemotherapy has considerable toxicity, each
patient needs a prudent assessment of the risks before ACT treat-
ment. Recently, several studies have to investigate the survival
beneﬁt of adjuvant chemotherapy in NSCLC with other impact fac-
tors such as age, sex, stage and gene signature [8–13]. However,there is no proper to assess adjuvant chemotherapy beneﬁt. In this
study, we aim to develop prediction models to distinguish who is
suitable for adjuvant chemotherapy and who should avoid adju-
vant chemotherapy in NSCLC.
Many studies described to develop classiﬁers for detection or
diagnosis of disease by using machine learning techniques. The
artiﬁcial neural network (ANN) is a kind of machine learning meth-
ods [14]. It works as humans apply knowledge gained from past
experience to new problems. ANN takes previously solved exam-
ples to build a system of ‘‘neurons’’ that makes new decisions, clas-
siﬁcations, and forecasts. The basic ANN receives many inputs (it
can be from original data, or from the output of other ANN). Each
input is connected to neurons with different weights. The output
of the neuron is produced by the activation function. In ANN
research ﬁeld, multi-layer perceptron (MLP) and radial basis func-
tion (RBF) are commonly used ANN model types, which have a
strong classiﬁcation ability. It can solve very complex distribution
pattern classiﬁcation problem, but there are some differences in
the structure and function. In which, MLP is the most widely used
ANN model type for classiﬁcation and regression in medical
research. MLP consists of three parts, including the input layer, hid-
den layer and output layer. The input layer neurons accept a large
2 Y.-C. Chen et al. / Journal of Biomedical Informatics 56 (2015) 1–7number of non-linear input. The output layer is the signal analysis
result that weighted, analyzed and transmitted via neurons. The
hidden layer is composed of many neurons and links all levels
between the input layer and output layer. The hidden layer can
have multiple layers which typically used one layer in MLP net-
works. MLP can distinguish data that are not linearly separable.2. Methods
To assess the prognostic beneﬁt of various parameters with
ACT, we analyzed multiple data sets in lung cancer. Previous stud-
ies [8–10] are using Cox Proportional Hazards Model to calculate
risk scores of gene signature values with survival time as prognos-
tic risk classiﬁcation threshold. According to the median risk score,
NSCLC patients were divided into low risk and high risk group.
Then, they observed the survival beneﬁt of ACT/non-ACT patients
in these two groups. However, median risk score is a prediction
value and has bias error. According bias error to create predictive
models will result in greater deviation. Hence, we used the median
survival time rather than the median risk score as the risk classiﬁ-
cation threshold. The ﬂowchart of our study is shown in Fig. 1.
2.1. Gene expression and clinical data collection
In recent years, a large number of genetic data generated due to
advances in high-speed gene expression measurement techniques.
Many studies have reported the combination with gene expression
data and other high-dimensional genomic data for survival analy-
sis [15–20]. In NSCLC studies, Zhu (2010) has provided a large
study comparing the complete clinical data (including: age, race,
sex, survival time, adjuvant chemotherapy, adjuvant radiation
therapy and stages) [8]. We downloaded NSCLC patients’ gene
expression raw data (CEL ﬁles) and clinical data from NCI
caArray database (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE68465) which is a repository of high-throughput gene
expression data and hybridization arrays, chips, and microarrays
[18]. These NSCLC data were recorded primarily from 4 institutes
and represent 442 NSCLC patients. After deleting duplicate data,
survival time missing value and ACT information unknown
patients, 280 NSCLC patients were included in this study. Of these,
82 attended the University of Michigan Cancer Center (UM), 72
attended the Mofﬁtt Cancer Center (HLM), 84 attended the
Memorial Sloan-Kettering Cancer Center (MSKCC), and 42 attended
the Dana-Farber Cancer Institute (DFCI). The clinical data included
patients’ survival times, age, diagnoses, stages, treatment, andFig. 1. Flow chart of building artiﬁcial neural network prediction model for
adjuvant chemotherapy beneﬁt classiﬁcation in non-small lung cancer.smoking history. All gene-expression proﬁling was performed
using HG-U133A Affymetrix microarray chips. Affymetrix U133A
array chip are about 22,000 probe sets corresponding to 14,500
well-characterized human genes. A more detailed description of
the clinical data can be found in supplement ﬁle I.
2.2. Data preprocessing and ACT-Associated Gene Signatures
We collected microarray gene expression data from 4 hospitals,
which used the same technology platform, for cross-laboratory
data comparisons. Raw data (CEL ﬁles) for microarray gene expres-
sion proﬁles were imported into the statistical program R. To avoid
the effects from variation in the technology rather than from bio-
logical differences between the RNA samples or between the
printed probes, we need to do normalization to adjuvant microar-
ray data. The expression variables were normalized and computed
using the MAS5 function in the microarray package of R. The MAS5
function includes background adjustment, normalization, and
summarization on Affymetrix microarray probe-level data.
Microarray chips contain thousands of gene expression data.
This type of high-dimensional data contains many more gene
expressions than the number of individuals represented. In addi-
tion, the data set contained censored information, which meant
that we could not directly establish a gene prediction model.
Thus, we needed to reduce the number of variables and ﬁnd a suit-
able subset of genes that correlated with survival time as the
inputs of a prediction model. The strategy of our approach to ﬁlter-
ing the genes included several steps:
2.2.1. Establish lung cancer related gene subset
OMIM is a comprehensive, authoritative compendium of
human genes and genetic phenotypes that contain information
on all known Mendelian disorders and over 12,000 genes. In our
previous study, we collect OMIM database lung cancer-related
gene list and mapping to their corresponding microarray
probe-id [21]. This can be narrowed down to facilitate the calcula-
tion of target genes. The advantage is that the results obtained will
easily explain their biological.
2.2.2. Quintile numeric conversion
All gene expression in accordance with its quintile values were
converted to class 1–5 (very low, low, normal, high and very high).
The purpose is to reduce individual differences in gene expression,
and to facilitate the transition to other inspection technologies for
future use.
2.2.3. ACT beneﬁt classiﬁcation
In order to build predictive models to assess which patients
appropriate to accept adjuvant chemotherapy, we need to classify
all patients into ACT-futile and ACT-beneﬁt groups. Since approxi-
mately 50% of these patients did not survive over 40 months, the
classiﬁcation threshold we set at 40 months. All patients can be
divided into ACT and observation (OBS) sets according to the treat-
ment method. In ACT set, patients who lived greater than
40 months represent that the patients get signiﬁcant ACT help.
Patients who lived less than 40 months represent that the patients
do not get signiﬁcant ACT help. These patients need to reduce the
damage by chemotherapy. In OBS set, patients who lived less than
40 months represent that the patients may need get ACT. Patients
who lived greater than 40 months represent that patients have a
good prognosis and do not need ACT. As shown in Fig. 2, all
patients were divided into two groups according to their survival
time and ACT information. Among them, patients who lived less
than 40 months with ACT or who lived greater than 40 months
without ACT were belonging to the ACT-futile group. And, patients
Fig. 2. The patient who lived less than 40 months with ACT or who lived greater
than 40 months without ACT were belonging to the ACT-futile group. And, the
patient who lived greater than 40 months with ACT or who lived less than
40 months without ACT were belonging to the ACT-beneﬁt group.
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40 months without ACT were belonging to the ACT-beneﬁt group.Table 1
Summary of 280 NSCLC patients.
DFCI HLM UM MSKCC
GENDER Male 23 36 36 31
Female 19 36 46 53
Median follow-up (month) 47.5 17.12 48 42.5
Average age at diagnosis 57.6 67.8 63.2 64.8
ADJUVANT_CHEMO Yes 23 13 15 28
No 19 59 67 56
ADJUVANT_RT No 42 54 67 602.2.4. Feature selection
To select which gene signatures to use in building the predic-
tion model, we calculated chi-square test value between variables
(genes) and ACT-beneﬁt/ACT-futile groups for each data set. We
identiﬁed the top 10 rank ACT beneﬁt correlated gene signatures
for each data set, and used the subset gene signatures as the sur-
vival beneﬁt predictive model variables. Calculate the chi square
value for gene expression and ACT-beneﬁt/ACT-futile, and select
the top 10 rank genes as the machine learning target genes.
Clinical data such as sex, age, T-stage and N-stage were also con-
sidered as ANN variables. The ten genes which were identiﬁed in
the previous process were used to train an ANN-Network. The dif-
ferent combinations of top ten genes were used as ANN input. The
ﬁnal input feature genes for optimal ANN models were evaluated
by using 10-fold cross validation and Kaplan–Meier survival anal-
ysis. In the end, in all combinations, the best results of ANN is
retained. In 10-fold cross-validation, the original data is randomly
split into 10 equal sized subsets. Of the 10 subsets, one subset is
kept as the validation data for testing the ANN model, and
the remaining 9 subsets are used as training data. The
cross-validation process is then repeated 10 times (the folds), with
each of the 10 subsets used exactly once as the testing data. The 10
validation data can be merged into a single data set, then the single
data can get a KM-curve estimation by using every case. The details
of 10-fold subsets can be found in supplement ﬁle IV.Unknown 0 1 0 0
Yes 0 17 15 24
Status Dead 22 57 47 39
Alive 20 15 35 45
N_Stage N0 28 48 59 52
N1 14 12 11 14
N2 11 12 18
NX 1
T_Stage T1 5 12 45 27
T2 37 48 34 53
T3 9 3 4
T4 32.3. Building prediction models
We used the most popular machine-learning method, Artiﬁcial
Neural Network (ANN), to model NSCLC survival. The ANN method
has been shown to improve the accuracy of prediction for cancer
survival outcomes [22]. We performed several types of ANN algo-
rithms to identify the optimal ANN architecture. Reliability was
assessed by cross-data set validation. The data sets were randomly
selected so that one source provided the training set and the others
provided the test set. All networks were trained using commercialsoftware (STATISTICA version 8.0). During the supervised training
stage, a data set is presented to the ANN with the correct outputs
available (beneﬁt classiﬁcation). Beneﬁt was classiﬁed according to
the median overall survival time (40 months) and ACT information.
Patients could not be divided into ACT-beneﬁt or ACT-futile groups
directly according to their gene expression values, so Patients who
lived less than 40 months with ACT or who lived greater than
40 months without ACT were belonging to the ACT-futile group,
and all other patients were assigned to the ACT-beneﬁt group.
Thereafter, the ANN was used for prediction. Because no perfect
method exists for designing an ideal ANN and the optimal number
of hidden nodes and iterations are unknown, the best design is
usually determined by trial and error [23]. To identify the optimal
model, we use a combination of different activation function and a
different number of hidden layer neurons to construct and train a
lot of various ANN architectures using the training data. All models
were tested with the test data to determine their predictive accu-
racy for risk classiﬁcation. The network showing the most accurate
classiﬁcation was retained.
2.4. Evaluation by Kaplan–Meier survival analysis and log-rank test
Many studies have using machine learning method to predict
patient survival. In this study, the prediction results contain cen-
sored data. It is not fair to use the general machine learning valida-
tion method to validate the prediction results with censored data,
and the prediction results may have no signiﬁcant. To evaluate the
prediction results with censored data, the Kaplan–Meier survival
analysis (KM-plot) is a good means. KM-plot is an estimator for
the survival function. In medical research, KM-plot is used to mea-
sure the patients’ survival time after treatment. An important
advantage of the KM-plot is that the method can take into account
censored data. The log-rank test is used to determine the signiﬁ-
cant differences in survival between groups, treatments, etc.
Several studies have used KM-plot to make sure their prediction
results were signiﬁcantly [8–12,15,16,18,19]. We use the mixed
methodology K-fold cross-validation and KM-plot to verify the pre-
diction results.
3. Results
We analyzed the microarray gene expression data from 280
NSCLC patients. Table 1 summarizes the initial analysis of data
Table 2
Summary of top 10 genes functions.
Rank Probe ID Gene symbol Chr. Summary Differential expression
(NSCLC vs normal)
1 208893_s_at DUSP6 12 The protein encoded by this gene is a member of the dual speciﬁcity protein
phosphatase subfamily
Down-regulated
2 204891_s_at LCK 1 The encoded protein is a key signaling molecule in the selection and maturation of
developing T-cells
Down-regulated
3 215085_x_at DLEC1 3 This gene is a functional tumor suppressor Down-regulated
4 203414_at MMD 17 This protein is expressed by in vitro differentiated macrophages but not freshly
isolated monocytes
Up-regulated
5 202886_s_at PPP2R1B 11 Mutations in this gene have been associated with some lung and colon cancers Up–regulated
6 202883_s_at PPP2R1B 11 Mutations in this gene have been associated with some lung and colon cancers Up-regulated
7 216105_x_at PPP2R4 9 Protein phosphatase 2A is implicated in the negative control of cell growth and
division
No data
8 207686_s_at CASP8 2 Sequential activation of this gene plays a central role in the execution-phase of cell
apoptosis
No data
9 210930_s_at ERBB2 17 This gene encodes a member of the epidermal growth factor (EGF) receptor family of
receptor tyrosine kinases
Up-regulated
10 206798_x_at DLEC1 3 This gene is a functional tumor suppressor Down-regulated
4 Y.-C. Chen et al. / Journal of Biomedical Informatics 56 (2015) 1–7from the 280 patients. All patients were classiﬁed in
ACT-beneﬁt/ACT-futile groups according to their survival time
and ACT information and used to ﬁnd the impact factors of the
ACT-related genes as well as the establishment of ANN prediction
module.3.1. Data preprocessing and ACT-Associated Gene Signatures
As mentioned in Section 2.2, we collected from the literatures
lung cancer related genes. Then we identiﬁed the ACT treatment
outcome with correlated genes from 4 microarray data sets by cal-
culating the chi-square value between lung cancer related gene
signatures and patient’s ACT treatment outcome. The top
10-ranked genes were selected for prediction model creation.
These probe genes included 208893_s_at (DUSP6), 204891_s_at
(LCK), 215085_x_at (DLEC1), 203414_at (MMD), 202886_s_at
(PPP2R1B), 202883_s_at (PPP2R1B), 216105_x_at (PPP2R4),
207686_s_at (CASP8), 210930_s_at (ERBB2), 206798_x_at
(DLEC1) on the Affymetrix U133A microarray chip (Table 2). In
Table 2, the gene differential expression data was retrieved fromFig. 3. MLP14-8-2 ANN model has 14 inputs, 8 hidden neurons and 2 outputs. In this cas
(LCK) and T-stage.‘‘Expression Atlas’’ database of EMBL-EBI (http://www.ebi.ac.uk/
gxa/).
We then divided patients into ACT-beneﬁt/ACT-futile groups
according to the patients’ survival times and ACT information for
ANN train (50%) and test (50%). After a lot of various ANN training
in trial and error procedure, we obtained 2 probes (2 genes) with
T-stage clinical data combination can get good prediction result.
These genes included 208893_s_at (DUSP6) and 204891_s_at
(LCK).3.2. The ANN prediction models
Following the methodology proposed in Section 2.3, we con-
structed and trained a lot of various ANN architectures using the
training data, and divided the NSCLC cases into ACT-beneﬁt and
ACT-futile groups according to 2 gene signatures and T-stage value.
As show in Fig. 3, the best result of ANN models is MLP14-8-2 with
logistic activation function. MLP14-8-2 means this ANN model has
14 inputs, 8 hidden neurons and 2 outputs. In this case, the 14
inputs represent the category values of 208893_s_at (DUSP6),e, the 14 inputs represent the category values of 208893_s_at (DUSP6), 204891_s_at
Table 3
Summary of the ACT-futile/ACT-beneﬁt group.
ACT-futile ACT-beneﬁt P-value
GENDER Male 82 44 0.21345
Female 89 65
Median follow-up (month) 55 17.6 P < 105
Average age at diagnosis 65 63.4 0.80251
ADJUVANT_CHEMO Yes 55 24 0.06587
No 116 85
ADJUVANT_RT No 138 85 0.58778
Unknown 1 0
Yes 32 24
Status Dead 79 86 P<105
Alive 92 23
N_Stage N0 118 69 0.56874
N1 30 21
N2 22 19
NX 1 0
T_Stage T1 65 24 0.00047
T2 101 71
T3 3 13
T4 2 1
Fig. 4. Kaplan–Meier Estimates of Survival predictions for train set, log-rank test P-
value < 10–5. Patients in the ACT-beneﬁt group obtained a lower median
(14.1 months) survival compared with ACT-futile patients (51.2 months).
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(input + output)/2, then a good prediction result can be obtained.
The ANN prediction model with PMML format can be found in sup-
plement ﬁle II. In this study, we adopted a two-stage evaluation.
The ﬁrst stage is the use of STATISTICA provides optimal NN tool
(e.g., train perf., select perf., test perf., train error, etc.) screening
better results. Because of the clinical data contains the censored
data (In the end of this study, patient has not died or missing con-
tact.), STATISTICA may have produced same training performance
neural network but ultimately performance in the survival analysis
may be very different. Hence, we used the Kaplan–Meier survival
analysis evaluation result to conﬁrm the optimal NN in the second
phase.3.3. Evaluation of prediction results
The Kaplan–Meier estimates of the survival function for the pre-
diction results for NSCLC are shown in Fig. 2. The log-rank test was
used to analyze differences in survival between the ACT-beneﬁt
and ACT-futile groups. Tables 3 and 4 summarize the classiﬁcation
results and gene expression level frequency count with chi-square
test of ACT-futile/ACT-beneﬁt group. In Fig. 4, Kaplan–Meier
Estimates of Survival predictions for train set, log-rank test
P-value < 105. Patients in the ACT-beneﬁt group obtained a lower
median (14.1 months) survival compared with ACT-futile patientsTable 4
Gene expression level frequency count with chi-square test in NSCLC.
Probe ID Gene symbol ACT-futile
1 2 3 4
208893_s_at DUSP6 8 3 6 36
204891_s_at LCK 1 23 64 70
215085_x_at DLEC1 65 62 37 5
203414_at MMD 0 1 6 59
202886_s_at PPP2R1B 0 9 108 51
202883_s_at PPP2R1B 0 0 6 118
216105_x_at PPP2R4 0 0 0 147
207686_s_at CASP8 10 70 84 7
210930_s_at ERBB2 56 101 12 2
206798_x_at DLEC1 11 69 81 9
All gene expression in accordance with its quintile values were converted to class 1–(51.2 months). In Fig. 5, Kaplan–Meier Estimates of Survival pre-
dictions for test set, log-rank test P-value < 105. Patients in the
ACT-beneﬁt group obtained a lower median (6 months) survival
compared with ACT-futile patients (40.5 months). The results show
that for NSCLC we could get good performance to predict ACT ben-
eﬁt groups using a cross-laboratory data set. In Table 5, the results
showed the 10-fold cross validation accuracy of ACT beneﬁt classi-
ﬁcation result. The Kaplan–Meier estimates of survival predictions
for 10-fold cross validation plotted in Fig. 6. Patients in the
ACT-beneﬁt group obtained a lower median (8.6 months) survival
compared with ACT-futile patients (43.2 months). The 10-fold
cross validation classiﬁcation accuracy was 65.71%. Most predic-
tion errors case belongs to the type II error. (There may cause by
an initial classiﬁcation error and unbalance of sample size. These
patients may not appropriate to accept ACT in nature.) The optimal
ANN architecture MLP was a standard feed-forward, fully con-
nected, backpropagation multi-layer perceptron. As show in
Table 6, we also used other machine learning methods (RBF,
SVM, Bayesian and K-Nearest) [24] to build prediction models,
and the MLP get best result. A more detailed description of other
machine learning results can be found in supplement ﬁle III.ACT-beneﬁt P-value
5 1 2 3 4 5
118 4 8 12 22 63 0.013483
13 1 17 49 28 14 0.108627
2 35 54 19 1 0 0.092715
105 0 0 1 28 80 0.136337
3 0 4 57 43 5 0.144498
47 0 0 0 71 38 0.075567
24 0 0 3 91 15 0.092638
0 5 35 67 2 0 0.210693
0 26 68 12 1 2 0.141043
1 10 48 49 2 0 0.324857
5 (very low, low, normal, high and very high).
Fig. 5. Kaplan–Meier Estimates of Survival predictions for test set, log-rank test P-
value < 10–5. Patients in the ACT-beneﬁt group obtained a lower median
(6 months) survival compared with ACT-futile patients (40.5 months).
Table 5
The prediction model performance in ACT beneﬁt classiﬁcation.
10-fold cross validation Prediction
ACT beneﬁt ACT futile
Observation ACT beneﬁt 35 74
ACT futile 22 149
Accuracy 65.7%
Fig. 6. Kaplan–Meier Estimates of Survival predictions for 10-fold cross validation,
log-rank test P-value < 10–5. Patients in the ACT-beneﬁt group obtained a lower
median (8.6 months) survival compared with ACT-futile patients (43.2 months).
Classiﬁcation accuracy was 65.71%.
Table 6
The comparison of different machine learning methods prediction result.
Bayesian SVM K-nearest RBF MLP
10-fold cross validation N/A 61.42% 45.71% N/A 65.71%
Test accuracy 66.40% 63.57% 40% 62% 70%
Sensitivity 15.60% 42.30% 90.40% 25.80% 44.40%
Speciﬁcity 98.80% 77.30% 10.20% 93.60% 87.20%
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We used the ANN approach to predict ACT beneﬁt because of its
ease of use and rapid results. The disadvantage of ANN was that it
was difﬁcult to explain its decisions in classifying the output vari-
able into ACT-beneﬁt or ACT-futile groups.
4.1. The featured genes
DUSP6 is a novel transcriptional target of p53 and regulates
p53-mediated apoptosis by modulating expression levels of Bcl-2
family proteins and is associated with cellular proliferation and
differentiation [25,26]. LCK is a member of the Src family of protein
tyrosine kinases (PTKs) and is a key signaling molecule in the selec-
tion and maturation of developing T-cells [27–29]. Several studies
have indicated the DUSP6 function in regulating genomic integrity
and sensitivity to chemotherapy in cancer [30–33]. Overexpression
of DUSP6 was promotes tumor development to cause refractory to
chemotherapy [32]. LCK is linked to higher resistance to platinum
complexes and other chemotherapeutics [34]. In this study, DUSP6
and LCK are highly association with the effectiveness of adjuvant
chemotherapy.
4.2. Study limitation
Many studies of NSCLC have reported their results with expres-
sion signatures. However, most studies are too small and without
clinical data. Only few datasets were included in this study.
Because this study used public database, some limitations exist.
First, the models may not generalize to other cancer types, because
surgery is mostly used to treat NSCLC. Second, the study did not
consider the impact of radon, asbestos, secondhand smoke, and
occupational carcinogens exposition, type and stage of a lung can-
cer, and history of adult pneumonia on patients. Moreover, vari-
ables generated by the surgical procedure, such as bleeding,
infection, pneumothorax, damage to nearby structures, risks from
general anesthesia, blood clots, and other factors to death are not
considered.
4.3. Conclusions
The results of this study showed that using gene signature pro-
ﬁles to predict ACT beneﬁt in NSCLC is feasible. The prediction
models can distinguish who is suitable for adjuvant chemotherapy
and who should avoid adjuvant chemotherapy. The key to this
analysis was identifying the pertinent genes and classiﬁcation.
Previous studies have used data from a single limited source to
build a prediction model, and the results might thus have been
affected by sample bias. To avoid sample bias, we combined data
from several sources to perform the cross-prediction. The majority
of previous studies have used methods other than ANN, whereas
we used ANN to construct a prediction models and used the sam-
ple sets to perform cross-laboratory training and prediction. The
results showed that the survival of cancer patients across four hos-
pitals predicted a good performance. However, the predictions
showed some inconsistencies across the data sets, which might
have been attributable to different medical treatments. Further
Y.-C. Chen et al. / Journal of Biomedical Informatics 56 (2015) 1–7 7research and clinical studies are recommended. Other types of can-
cer should be investigated to improve the prognostic methods of
cancer patients. Chemotherapy drugs are often toxic, often causes
bone marrow suppression, nausea, vomiting, diarrhea, hair loss,
infertility or other side effects. When the side effects happened,
patients need with additional medication. Hence, we hope that this
study can help reduce the ineffective medical practices to avoid the
waste of medical resources (e.g. avoid unnecessary chemotherapy
treatment, reduce waste drugs ineffective use. Reduce pain in can-
cer patients).
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